A sensitive immunoassay for flunitrazepam and metabolites.

Area of Science:

• Forensic toxicology
• Analytical chemistry
• Immunochemistry

Background:

• Flunitrazepam (Rohypnol) is a benzodiazepine with potential for misuse.
• Accurate detection of flunitrazepam and its metabolites in biological samples is crucial for clinical and forensic applications.
• Existing analytical methods may require specialized equipment and expertise.

Purpose of the Study:

• To develop a novel immunoassay for detecting flunitrazepam and/or cross-reacting metabolites in urine.
• To compare the performance of the developed immunoassay with gas chromatography-mass spectrometry (GC-MS).
• To assess the duration of detectability of flunitrazepam and its metabolites in urine post-ingestion.

Main Methods:

• Volunteers were administered varying doses of flunitrazepam (0.5-4 mg).
• Urine samples were collected for up to two weeks post-ingestion.
• An enzyme-linked immunosorbent assay (ELISA) was developed using a specific antibody and a drug-enzyme conjugate (7-aminoflunitrazepam-horseradish peroxidase).

Main Results:

• Significant levels of flunitrazepam and/or cross-reacting metabolites were detected in urine for up to one week post-ingestion.
• The developed immunoassay demonstrated selectivity, with only diazepam showing cross-reactivity at a high concentration (1000 µg/L).
• Results from the immunoassay were compared with GC-MS, indicating comparable detection capabilities within the study's scope.

Conclusions:

• The developed immunoassay is a viable and sensitive method for detecting flunitrazepam and its metabolites in urine.
• The assay provides a detection window of up to one week, which is clinically relevant.
• The immunoassay offers a selective and potentially more accessible alternative for drug screening compared to traditional methods like GC-MS.